Skyroot and Redcliffe Labs Launch India's First Space-Diagnostics Partnership

Hyderabad-based Skyroot Aerospace and diagnostic provider Redcliffe Labs have partnered to study how diagnostic materials behave in space. The collaboration marks India's first joint venture between the private space sector and the diagnostics industry.

Under the initial mission, titled DRIFT-1, the partners will send dry diagnostic reagents into Low Earth Orbit (LEO). These samples will remain in orbit for 90 days, allowing researchers to evaluate their stability and performance under the influence of microgravity, radiation, and other extreme orbital conditions. The results will be compared against a control group maintained on Earth to determine the specific impact of the space environment.

The Intersection of Health and Orbit

Skyroot Aerospace, a private aerospace manufacturer founded by former ISRO scientists, provides the launch capabilities necessary to bridge the gap between healthcare and space science. Redcliffe Labs, a Y Combinator-backed omnichannel diagnostic service provider, brings the medical expertise required to analyze reagent stability. Together, they aim to create "flight-heritage" datasets that document how critical medical chemicals react outside Earth's atmosphere.

"The most transformative breakthroughs often happen at the intersection of disciplines that rarely come together," said Dheeraj Jain, chairman and co-founder of Redcliffe Labs. Pawan Kumar Chandana, Skyroot co-founder and CEO, added that a diagnostics leader taking its expertise to orbit is the exact type of use case the company hopes to enable by "opening space for all."

Implications for Earth and Beyond

The findings from DRIFT-1 could fundamentally change how astronaut health is monitored during long-term space missions. By developing more resilient diagnostic technologies that can function in LEO, the partnership seeks to ensure that critical health monitoring remains viable during deep-space exploration.

Beyond the stars, the research has immediate terrestrial applications. Studying reagents that can withstand extreme conditions without the need for conventional cold-chain infrastructure—the refrigerated supply chain usually required for medical tests—could revolutionize healthcare delivery in remote or challenging environments on Earth where electricity and refrigeration are scarce.

Future Outlook

As the DRIFT-1 mission progresses, the industry will be watching for data on whether dry reagents maintain their integrity over the 90-day window. If successful, this framework could lead to a new category of space-hardened medical tools. While the initial focus remains on stability, the long-term goal is to establish a repeatable pipeline for testing medical diagnostics in orbit, potentially expanding the scope of what can be monitored in real-time during spaceflight.